GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Silence Therapeutics PLC (OTCPK:SLNCF) » Definitions » Shiller PE Ratio

Silence Therapeutics (Silence Therapeutics) Shiller PE Ratio : (As of Jun. 06, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Silence Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Silence Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Silence Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Silence Therapeutics Shiller PE Ratio Chart

Silence Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Silence Therapeutics Quarterly Data
Jun18 Dec18 Jun19 Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Silence Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Silence Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Silence Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Silence Therapeutics's Shiller PE Ratio falls into.



Silence Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Silence Therapeutics's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Silence Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.018/131.6000*131.6000
=-0.018

Current CPI (Mar. 2024) = 131.6000.

Silence Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
200806 -4.018 86.600 -6.106
200812 -1.568 87.100 -2.369
200906 -2.177 88.100 -3.252
200912 -2.386 88.900 -3.532
201006 -1.861 90.200 -2.715
201012 -0.530 91.700 -0.761
201106 -0.786 93.500 -1.106
201112 -0.179 95.000 -0.248
201206 -3.188 95.600 -4.389
201212 1.155 97.300 1.562
201306 -0.130 98.000 -0.175
201312 -0.190 99.200 -0.252
201406 -0.195 99.800 -0.257
201412 -0.164 99.900 -0.216
201506 -0.111 100.100 -0.146
201512 -0.049 100.400 -0.064
201606 -0.097 101.000 -0.126
201612 -0.066 102.200 -0.085
201706 -0.101 103.500 -0.128
201712 0.075 105.000 0.094
201806 -0.165 105.900 -0.205
201812 -0.175 107.100 -0.215
201906 -0.146 107.900 -0.178
201912 -0.151 108.500 -0.183
202006 -0.171 108.800 -0.207
202009 -0.142 109.200 -0.171
202012 -0.203 109.400 -0.244
202103 -0.135 109.700 -0.162
202106 -0.184 111.400 -0.217
202109 -0.152 112.400 -0.178
202112 -0.140 114.700 -0.161
202203 -0.113 116.500 -0.128
202206 -0.164 120.500 -0.179
202209 -0.082 122.300 -0.088
202212 -0.160 125.300 -0.168
202303 -0.115 126.800 -0.119
202306 -0.121 129.400 -0.123
202309 -0.092 130.100 -0.093
202312 -0.158 130.500 -0.159
202403 -0.018 131.600 -0.018

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Silence Therapeutics  (OTCPK:SLNCF) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Silence Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Silence Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Silence Therapeutics (Silence Therapeutics) Business Description

Traded in Other Exchanges
Address
72 Hammersmith Road, London, GBR, W14 8TH
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risk of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.